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Abbreviations
and Acronyms
apo = apolipoprotein
CE = cholesteryl esters
HPLC = high-pressure liquid
chromatography
KDdiAPC = 1-(palmitoyl)-2-
(4-keto-dodec-3-ene-dioyl)
phosphatidylcholine
KOdiAPC = 1-(palmitoyl)-2-
(5-keto-6-octene-dioyl)
phosphatidylcholine
MRM = multiple reaction
monitoring
MS/MS = tandem mass
spectrometry
nLDL = native low-density
lipoprotein
OxCE = oxidized cholesteryl
esters
OxLDL = oxidized low-
density lipoprotein
OxPL = oxidized
phospholipids
PAzPC = 1-palmitoyl-2-
azelaoyl-sn-glycero-3-
phosphocholine
PC = phosphatidylcholine
PC-OxPL = phosphocholine-
containing oxidized
phospholipids
PE =
phosphatidylethanolamine
PGPC = 1-palmitoyl-2-
glutaroyl-sn-glycero-3-
phosphocholine
PONPC = 1-palmitoyl-2-(9’-
oxo-nonanoyl)-sn-glycero-3-
phosphocholine
POVPC = 1-palmitoyl-2-(5’-
oxo-valeroyl)-sn-glycero-3-
phosphocholine
PUFA = polyunsaturated
fatty acid
SVG = saphenous vein graft
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1962Cardiovascular disease remains
one of the largest contributors to
morbidity and mortality in the
Western world (1) and is pro-
gressively increasing in devel-
oping nations. Percutaneous
interventions are dominant ap-
proaches for the treatment of acute
coronary syndromes and symp-
tomatic obstructive coronary artery
disease. Periprocedural complica-
tions, such as acute thrombosis and
distal embolizationand slow-orno-
reﬂow phenomenon, continue to
remain limitations of procedural
success. For example, despite the
use of optimal antiplatelet ther-
apies and statins, a signiﬁcant
number of patients develop peri-
procedural myocardial infarction,
which identiﬁes patients at worse
long-term prognosis (2). Like-
wise, the risk of stroke/transient
ischemic attack after carotid
stenting is 1% to 4%, despite
the use of embolic protection
devices. In renal artery inter-
ventions, worsening of blush grade
or decrease in frame count, pre-
sumably caused by distal em-
bolization, has been associated
with ultrasound-detected lipid-
rich plaques and suboptimal clin-
ical response (3). Although the
cause of periprocedural events is
multifactorial, identiﬁcation of bio-
active embolized bioactive material
thatmediates adverse clinical events
may allow the development of tar-
geted therapies to further minimize
adverse clinical events.
A large component of unsta-
ble atherosclerotic plaques is the
lipid core (4), which is primarilycomposed of cholesterol crystals, oxidized low-density lipo-
protein (OxLDL), and apoptotic and necrotic macrophage-
derived foam cells (5,6). A large body of evidence
shows that oxidized phospholipids (OxPL) and speciﬁcally
phosphocholine-containing OxPL (PC-OxPL) play a major
role in the adverse biological activities of OxLDL (7–9). PC-
OxPL represent a heterogeneous group of bioactive mole-
cules that have been shown to promote cell death, platelet
aggregation (10), monocyte recruitment, and vasoconstric-
tion. Polyunsaturated fatty acids (PUFAs) on cholesteryl
esters (CE) undergo similar modiﬁcations as the PUFA
on phospholipids under oxidative stress. Such oxidizedcholesteryl esters (OxCE), in which the PUFA is oxidized but
not the cholesterol moiety, are also abundant in OxLDL and
atherosclerotic plaques (11–13) and have been shown to be
biologically active, initiating proinﬂammatory macrophage
activation and promoting foam cell formation (14,15).
Plaque components released during iatrogenic plaque
rupture may result not only in mechanical obstruction
because the size of the particles is larger than the microvessels
but also in functional obstruction mediated by vasocon-
striction, platelet aggregation, neutrophil activation, and
inﬂammation mediated by bioactive oxidized lipids me-
chanically released from the site of storage or sequestration
(16–18). However, oxidized lipids released during percuta-
neous procedures may be the most clinically relevant because
they may lead to adverse clinical events. Speciﬁcally, these
compounds are small enough to pass through ﬁlter devices
and affect the distal vessels and microcirculation. In this
study, we hypothesized that performance of percutaneous
interventions results in iatrogenic plaque disruption and/or
rupture leading to distal release of bioactive oxidized lipids.
Methods
See the Online Appendix.
Results
All patients underwent clinically indicated interventions.
Of the 24 distal embolic protection devices analyzed, 17
FilterWire EZ (Boston Scientiﬁc, Natick, Massachusetts)
systems were used in saphenous vein grafts (SVGs), 2
FilterWire EZ systems were used in the renal arteries, 2
Spider RX (ev3 Inc., Plymouth, Minnesota) systems were
used in the superﬁcial femoral arteries, and 3 Rx Accunet
(Abbott Vascular, Abbott Park, Illinois) systems were used
in the carotid arteries. The distal embolic protection devices
were deployed before balloon angioplasty or stent placement
in all cases. The ﬁrst 12 ﬁlters were collected without ac-
companying clinical information. Table 1 represents a brief
clinical background of the remaining 12 patients.
Analysis of unoxidized phospholipids and PC-OxPL. To
identify PC-OxPL molecules within recovered ﬁlter material,
known PC-OxPL standards PGPC, 1-palmitoyl-2-(9’-oxo-
nonanoyl)-sn-glycero-3-phosphocholine (PONPC), 1-palmi-
toyl-2-azelaoyl-sn-glycero-3-phosphocholine (PAzPC),
1-palmitoyl-2-(5’-oxo-valeroyl)- (POVPC), 1-(palmitoyl)-2-
(5-keto-6-octene-dioyl) phosphatidylcholine (KOdiAPC), and
1-(palmitoyl)-2-(4-keto-dodec-3-ene-dioyl) phosphatidylcho-
line (KDdiAPC) were ﬁrst separated on normal-phase high-
pressure liquid chromatography (HPLC) with precursor ion
(m/z 184) scanning mode. Figure 1A shows the total ion
chromatogram of the separated PC-OxPL standards.
KOdiAPC (peak 1), PONPC (peak 2), POVPC (peak 3),
KDdiAPC (peak 4), PAzPC (peak 5), and PGPC (peak 6)
eluted in order of mass and polarity. Figure 1B shows the
molecular ions (positive ions) derived from the elution of
Table 1
Embolic Protection Devices, Vascular Territory, and Baseline Clinical Characteristics of the Patients Undergoing
Percutaneous Intervention Who Had Clinical Data Recorded
Sample Device Vascular Bed Age, yrs DM HTN [LDL-Cholesterol
1 FilterWire EZ (Boston Scientiﬁc, Natick Massachusetts) SVG 66 þ þ þ
2 FilterWire EZ SVG 65 - þ þ
3 FilterWire EZ SVG 70 - þ -
4 FilterWire EZ SVG 69 þ þ þ
5 FilterWire EZ SVG 58 - - þ
6 FilterWire EZ Renal artery 78 þ - þ
7 FilterWire EZ Renal artery 59 þ þ þ
8 Spider RX (ev3 Inc., Plymouth, Minnesota) SFA 71 þ þ þ
9 Spider RX SFA 80 - - þ
10 Rx Accunet (Abbott Vascular, Abbott Park, Illinois) Carotid 59 þ þ -
11 Rx Accunet Carotid 68 - þ þ
12 Rx Accunet Carotid 76 - þ -
DM ¼ diabetes mellitus; HTN ¼ hypertension; SFA ¼ superﬁcial femoral artery; SVG ¼ saphenous vein graft.
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1963standards corresponding to the precursor [M+H]+ that were
collisionally activated to generate the phosphocholine ion at
m/z 184 showing m/z corresponding to known standards.
Figures 1C to 1H show the elution time for each PC-OxPL
standard, with KOdiAPC having the earliest elution time
with a retention time of 17.5 min and PGPC eluting last
with a retention time of 23.6 min.
We next analyzed the lipid extracts from embolic ﬁlter
material by precursor ion scanning (m/z 184) allowing for
identiﬁcation of PC-OxPL. Phosphatidylcholine (PC)
eluted earliest, followed by sphingomyelin and lysoPC
(Fig. 2). Extracts from ﬁlter material showed an abundance
of PC-OxPL molecules compared with extracts of non-
oxidized, native low-density lipoprotein (nLDL) (Fig. 2A).
As an example, compounds eluting between 17.5 and 19.2
min represent a large component of fragmented PC-OxPL
compared with nLDL (Fig. 2B). There were also other
ions present in the plaque material not seen in nLDL (e.g.,
m/z 678, 822, 832, 850). Given that the other ions eluted
with other PC-OxPL molecules, they likely represent both
fragmented and polyoxygenated unsaturated PC molecules.
For example, ion 678 on the basis of mass and the elution
pattern could represent the 18:0 fatty acid in the sn-1 po-
sition with C9 aldehyde moiety in the sn-2 position.
The retention time observed for the synthetic PONPC
determined by the expected [MþH]þ at m/z 650.5
(Fig. 2C) was at 18.8 min, and this speciﬁc ion transition
(m/z 650/184) was present in low abundance in nLDL
but the most abundant ion observed in the SVG ﬁlter ma-
terial elution in this retention time region (Fig. 2B). Within
plaque lipid extracts, this approach was used to identify 6
OxPL on the basis of the correlation of retention times to
the oxidized standards available and to the appearance of
these speciﬁc ion transitions at the appropriate retention
times during analysis of the SVG material.
To increase the sensitivity by using multiple reaction
monitoring (MRM) scanning, the relative mass of PC-OxPL
in the ﬁlters from various vascular beds was quantiﬁed by
comparing with the internal standard (1,2-dinonanoyl-sn-glycero-3-phosphocholine) that was added during lipid
extraction. Figure 3 demonstrates the MRM analysis of pla-
que material, with peaks corresponding in retention time to
known synthetic standards. OxLDL lipid extracts were
analyzed in the same way. We next compared the levels of
PC-OxPL within different vascular beds and OxLDL. As a
percent of identiﬁed PC-OxPL, the most abundant PC-
OxPL was PONPC, which represented approximately 50%
of identiﬁed PC-OxPL across different vascular beds. This
was also the case when lipid extracts from different vascular
beds were analyzed, showing PONPC as the most abundant
PC-OxPL molecule, with KDdiAPC representing the
smallest fraction (Fig. 4).
By using both positive and negative ionization modes
(positive for PC, sphingomyelin, and lysoPC, and negative
for phosphatidylethanolamine [PE], CL, PG, PS, and PI),
the total phospholipid proﬁle in SVG samples was deter-
mined (Fig. 5A). The most abundant phospholipids were of
the PC class (37.82%), followed by sphingomyelin (31.06%),
PE, lysoPC, PC-OxPL, and lysoPE, with other phospho-
lipids in lesser amounts. When compared with copper-
oxidized LDL (OxLDL) (Fig. 5B), the material recovered
from SVGs had increased PE levels (15.40% vs. 1.63%;
p ¼ 0.003). This could represent cellular debris in the
recovered material because PE represents a larger portion of
total phospholipids in macrophages and smooth muscle cells
(19). Material from SVGs also contained more lysoPC
(4.84% vs. 0.35%; p ¼ 0.0001) and lysoPE (3.95% vs.
0.08%; p ¼ 0.0001), but less PC-OxPL (4.61% vs. 7.65%;
p < 0.0001) compared with OxLDL. It is important to note
that the OxLDL sample had been dialyzed during prepa-
ration, leading to loss of lysoPC and possibly other phos-
pholipid species, which inﬂuences these comparisons (20).
Additional OxPL molecular species were present in
these SVG samples when detailed analysis of the liquid
chromatography tandem mass spectrometry (MS/MS) data
was carried out. However, on the basis of the relative
abundance of an internal standard of all observed precursor
ions of m/z 184, themajority of the ion current was accounted
Figure 1 Normal-Phase LC-MS/MS Analysis Standard Fragmented PC-OxPL Molecules
(A) Total ion chromatogram from normal-phase precursor ion scan (m/z 184) liquid chromatography tandem mass spectrometry (LC-MS/MS) of 1 ng of each compound.
1-(palmitoyl)-2-(5-keto-6-octene-dioyl) phosphatidylcholine (KOdiAPC) (peak 1), 1-palmitoyl-2-(9’-oxo-nonanoyl)-sn-glycero-3-phosphocholine (PONPC) (peak 2), 1-palmitoyl-
2-(5’-oxo-valeroyl)-sn-glycero-3-phosphocholine (POVPC) (peak 3), KDiAPC (peak 4), 1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine (PAzPC) (peak 5), and 1-palmitoyl-
2-glutaroyl-sn-glycero-3-phosphocholine (PGPC) (peak 6). (B) Averaged mass spectra of standard fragmented phosphocholine-containing oxidized phospholipids (PC-OxPL)
molecules. (C–H) Ion chromatographs of the synthetic standards and their speciﬁc retention times. Calibration curves on the basis of co-injection with 1,2-dinonanoyl-sn-glycero-
3-phosphocholine were performed for each compound.
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1964for by the 6 PC-OxPL described earlier. Detailed experiments
are necessary to fully structurally characterize these additional
species.
Analysis of OxCE. The presence of OxCE was further
analyzed in 4 additional specimens using a semiquantitative
HPLC-MS/MS method. Data were collected in MRM
mode using transitions corresponding to CE(18:2),
CE(20:4), CE(22:6), and their major oxidation products, for
example, oxo-, hydroxy-, hydroxy-epoxy-, and hydroperoxy-
CEs, as previously described (12,21). The chromatograms
of major CE and OxCE species revealed readily detec-
table quantities of CE oxidation products in each ofthe 4 samples (Fig. 6A). The lack of positional
speciﬁcity, speciﬁcally the equal abundance of 9- versus
13-hydroperoxy-linoleic CE (the 2 major peaks of the
“hydroxy” series), suggested that the observed oxidation
products were formed chieﬂy through nonenzymatic mech-
anisms, a result consistent with previous analyses of OxCE
extracted from advanced femoral and popliteal endarterec-
tomy specimens (12,21). However, it should be noted
that this observation does not preclude a contributing
enzymatic component. The extent of CE oxidation varied
markedly between samples. Certain chromatograms sug-
gested a preponderance of oxidized species (Fig. 6A, top),
Figure 2 Normal-Phase LC-MS/MS Analysis of Lipid Extracts From SVGs Compared With nLDL
The ﬁlter with accompanying yellow debris is shown in the inset (A). Total ion chromatogram of precursor ions (m/z 184) for plaque material (dotted line) and native low-density
lipoprotein (nLDL) (solid line). Mass spectra from retention time 17.5 to 19.2 min for nLDL (B) and (C) plaque material. lysoPC ¼ lysophosphatidylcholine; PC ¼ phospha-
tidylcholine; SM ¼ sphingomyelin.
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1965whereas others showed less CE oxidation (Fig. 6A, bottom).
Semiquantitative analysis of these results indicated the overall
content of OxCE, as a percentage of the total CE, ranged
from 11% to 92% in the individual ﬁlters (Fig. 6B). Further
analysis of individual CE species and their oxidation prod-
ucts revealed the major acyl component was 18:2 (linoleic),
followed by 20:4 (arachidonic), and 22:6 (docosahexaenoic)
(Fig. 6C). The relative abundance of OxCE species followed
directly from this acyl distribution; oxidation products of
CE(18:2) were the most abundant followed by oxidation
products of the less abundant, highly unsaturated species
CE(20:4) and CE(22:6).
Enzyme-linked immunosorbent assays and immuno-
chemical staining evidence of the presence of OxPL.
Complementary immunochemical techniques were used to
demonstrate the presence of OxPL in the recovered plaque
material, as well as the major plasma carriers of PC-OxPL,
namely, lipoprotein(a) and plasminogen. This was accom-
plished by sonication of the ﬁlter materials in phosphate-
buffered saline, which were then directly plated on microtiter
well plates; the different moieties were measured by enzyme-
linked immunosorbent assay techniques using antibodiesspeciﬁc for OxPL, apolipoprotein (apo) B-100, apo(a), and
plasminogen, and the data were expressed as relative light units
per 100 ms. The mean  SD value was 11,342  13,220 for
OxPL, 8,114  9,524 for apo(a), 6,058  10,591 for apoB-
100, and 2,103  1,602 for plasminogen, which represent
values approximately 5 times above background. Because
different secondary antibodies were used in each assay, a direct
comparison of the relative amounts of each component cannot
be made.
Immunochemical methods also directly conﬁrmed the
presence of OxPL by immunostaining with antibody E06,
which binds to the PC headgroup of oxidized but not
normal phospholipids (Fig. 7). In addition, prominent
staining was noted for malondialdehyde epitopes, repre-
senting another well-deﬁned oxidation-speciﬁc epitope, in
this case epitopes of unstable 3-carbon dialdehyde that binds
to proteins in the lesion.
Discussion
This study documents the release and capture of OxPL and
OxCE from multiple vascular beds after percutaneous
Figure 3
Identiﬁcation of PC-OxPL Molecules Within Plaque Material From Filter Retrieved From Percutaneous Coronary Intervention in
Plaque Material
Single ion chromatograms of fragmented PC-OxPL molecules within retrieved plaque material (A) KOdiAPC, (B) PONPC, (C) POVPC, (D) 1-(palmitoyl)-2-(4-keto-dodec-3-ene-dioyl)
phosphatidylcholine (KDdiAPC), (E) PAzPC, and (F) PGPC. Retention times corresponded to known standards.
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1966arterial interventions using distal protection devices in he-
modynamically signiﬁcant lesions from symptomatic pa-
tients. These ﬁndings were demonstrated consistently with a
variety of techniques, including liquid chromatography MS/
MS, enzyme-linked immunosorbent assays, and immuno-
histochemistry. The release of OxPL is consistent with
the presence of these proinﬂammatory mediators in symp-
tomatic lesions (7), the commonalities of their proathero-
genic role in multiple vascular beds, and their potential role
in mediating periprocedural and spontaneous clinical events.
The current study demonstrated that the majority of
phospholipids identiﬁed consisted of unoxidized PC, PE,
and sphingomyelin, with PC-containing OxPL representing
approximately 5% of the total phospholipid content. The
distribution of phospholipids present in distal protection
devices was similar to in vitro–generated OxLDL, which
was produced by isolating LDL from normolipidemic
donors and exposing it to copper sulfate. This provides
further support for evidence that OxLDL is generated
in vivo and in clinically relevant lesions that drive the need
for treatment (5,21). The most abundant PC-containingOxPL was PONPC, which represented approximately
50% of the entire mass of fragmented PC-containing
phospholipids, and is likely derived from phospholipids
containing linoleic acid on the basis of its nonanoyl
component that is fragmented at the carbon double bond
present at this position. Other well-characterized bioactive
PC-containing OxPL also were present, including POVPC,
PGPC, and KOdiAPC (7,22). Prior studies have demon-
strated that these OxPL are present in OxLDL and human
atherosclerotic lesions and are associated with a variety of
proinﬂammatory and proatherogenic properties. For
example, they mediate endothelial/monocyte dysfunction
and bioactivity (23,24) and are important ligands for scav-
enger receptors on macrophages (22,25) and platelets (10),
which in turn lead to foam cell formation, release of in-
ﬂammatory cytokines, and platelet aggregation (5,26,27).
The current observations derived from material captured
in distal protection devices are generally consistent with prior
data from autopsy material or endarterectomy specimens
demonstrating the presence of a variety of OxPL (26,28).
The relative proportions of OxPL in different studies are
Figure 4 Distribution of PC-OxPL Recovered From Distal Protection Filter Devices From Different Vascular Beds
(A) Concentration of PC-OxPL within different vascular beds on the basis of dilution in 1 ml of phosphate-buffered saline before extraction. Because of larger amounts of plaque
recovery from saphenous vein graft (SVG) interventions, there are higher levels of PC-OxPL within SVG samples. (B) Relative distribution of PC-OxPL from different vascular beds
compared with OxLDL. All samples were analyzed in triplicate in normal-phase multiple reaction monitoring (MRM) LC-MS/MS (SVG: n ¼ 5, peripheral n ¼ 4, carotid n ¼ 3).
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1967somewhat different, but this may be attributed to the fact
that at autopsy or during endarterectomy, the entire plaque is
removed and subjected to lipid extraction, as opposed to
embolic material that could represent material from the most
friable part of the plaque that is released after barotrauma of
the devices used to dilate the lesions. These observations also
are consistent with a comprehensive immunohistological
study from our group in coronary autopsy and carotid end-
arterectomy specimens (5), in which antibodies directed to
oxidation-speciﬁc epitopes, apoB, and lipoprotein(a) were
used to immunostain intimal xanthomas, pathological
intimal thickening, early and late ﬁbroatheromas, thin-cap
ﬁbroatheromas, and ruptured plaques. It was demonstrated
that OxPL were present in early lesions but increased sub-
stantially in content as lesions progressed. In particular,
OxPL were abundantly present in foamy macrophages, un-
der the ﬁbrous cap and in the necrotic core, and most
prevalent in ruptured plaques. These data are consistent with
our prior ﬁndings that OxPL plasma levels increase acutely
after acute coronary syndromes (29) and after percutaneous
coronary intervention (16) and are strongly associated with
angiographically determined coronary artery disease (30) and
native coronary artery chronic total occlusions (6). Further-
more, elevated levels of OxPL, as measured by the OxPL/
apoB assay, independently predict 15-year cardiovasculardisease event rates and reclassify approximately 30% of pa-
tients into higher- or lower-risk categories, conﬁrming their
clinical relevance (31).
The most abundant OxCE molecules present in distal
protection devices were isomers of singly and doubly oxidized
forms of cholesteryl linoleate CE(18:2), e.g., hydroxy- and
hydroperoxy-CE(18:2). Similar oxidation products of
CE(20:4) and CE(22:6) were detectable but present in lower
quantities. Hutchins et al. (12) recently showed the presence
of a variety of OxCE within atherosclerotic plaques from
femoral artery endarterectomy specimens that represented
approximately 20% of the total CE pool. They also showed
that OxCEs are mainly present at the lipid core of the plaque
with imaging mass spectrometry. Of note, most of the
oxidized fatty acyl groups were derived from CE(18:2), but
not from triglycerides in the plaques. Truncated,u-oxidized-
CEs (e.g., C9- and C5-aldehydes) and hydroxy- and
hydroperoxy-CE species were identiﬁed in plaque material.
In our study, aldehydes represented a minor OxCE fraction,
whereas epoxy and hydroperoxy moieties constituted a ma-
jority of OxCE. This was in contrast with OxPL, the ma-
jority of which were aldehydes. This deviation in OxCE and
OxPL molecular species found in distal protection devices
may suggest the different mechanisms of CE and phos-
pholipid oxidation, e.g., enzymatic versus nonenzymatic,
Figure 5
Relative Total Phospholipid Composition of Embolized
Material Obtained in Saphenous Vein Graft Filters And
From LDL Oxidized In Vitro
(A) Total phospholipid composition of ﬁlter material recovered from SVG in-
terventions. The data represent an average of 4 samples analyzed in triplicate. (B)
Samples of OxLDL also were analyzed in triplicate by normal-phase high-pressure
liquid chromatography (HPLC)-MS/MS MRM scanning as a comparator. Phos-
pholipid classes were quantitated on the basis of class-speciﬁc internal stan-
dards. Percent represents total phospholipid. LPC ¼ lysophosphatidylcholine;
PC ¼ phosphatidylcholine; PE ¼ phosphatidylethanolamine; PG ¼ phosphatidyl-
glycerol; PI¼ phosphatidylinositol; PS ¼ phosphatidylserine; SM¼ sphingomyelin.
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1968and/or the different susceptibility of CE and phospholipid
hydroperoxides to form breakdown aldehyde products. The
18:2 and 20:4 CE are the preferential substrate for
15-lipoxygenase, the enzyme present in human atheroscle-
rotic lesions and important in in vivo LDL oxidation, as
shown in murine atherosclerosis models (32). It has also been
demonstrated that once OxCE are formed, the oxidized acyl
chains can be hydrolyzed from OxCE and then re-esteriﬁed
into phospholipids to form OxPL (33). Further, it is also
possible that enzymatic processes, mediated for example by
15-lipoxygenase, ﬁrst initiate CE peroxidation and then
nonenzymatic pathways predominate as the lesions progress
and mature, leading to accumulation of aldehydic products.
The fact that we observed no positional speciﬁcity among
OxCEs suggested that nonenzymatic oxidation was domi-
nant, but it certainly does not rule out enzymatic initiation or
ampliﬁcation of CE oxidation.
Clinical implications. These ﬁndings provide a novel
mechanism for the beneﬁt of distal protection devices in
potentially reducing periprocedural events, by preventingembolized plaque material with its cargo of OxPL and
OxCE from entering the microcirculation. OxPL have acute
detrimental effects on endothelial function (7,34), including
increasing permeability by breaking down cell junctions and
stress ﬁbers, releasing proinﬂammatory cytokines such as
interleukin-8 and monocyte chemoattractant protein-1,
quenching of nitric oxide, and enhancing platelet aggrega-
tion. These effects may lead to attraction of proinﬂammatory
cells, vasoconstriction, and microvascular obstruction.
The use of distal protection devices, compared with human
autopsy or endarterectomy specimens, allows plaque material
to be obtained from the iatrogenic plaque rupture of speciﬁc
lesions of deﬁned geometry and potentially represents the
most clinically relevant embolized debris. Furthermore, the
ﬁlter pores are generally approximately 90 to 110 mm in
diameter, and smaller-sized fragments and soluble mediators
not attached to larger fragments will pass through the ﬁlter, as
shown for oxidized lipids in venous samples collected after
percutaneous coronary intervention without distal protection
(5,16,29).
Clinical evidence of the potential role of CE is provided
by near-infrared spectroscopy (35,36), which detects lipid-
rich plaque composed mostly of CE, and by intravascular
ultrasound virtual histology that detects the lipid-rich
necrotic core (37). It is not known whether OxCE are
imaged with near-infrared spectroscopy. This study suggests
that developing techniques to image OxCE within this
larger pool of cholesteryl esters may provide more precise
risk stratiﬁcation of periprocedural events and spontaneous
plaque rupture. It would also allow performance of studies to
follow the natural history of the role of oxidized lipids in
clinical event prediction, similar to the PROSPECT (Pre-
dictors of Response to CRT) study (38), and to determine
the efﬁcacy of pharmacological agents. We have developed
techniques to image these oxidized lipids in animal models
using targeted nanoparticles containing oxidation-speciﬁc
antibodies with nuclear and magnetic resonance imaging
techniques (39) or using ﬂuorescent protein-tagged oxida-
tion-speciﬁc antibodies (40), which ultimately may be
modiﬁed and coupled to invasive modalities as molecular
imaging probes in humans. In animal studies of athero-
sclerosis regression, oxidized lipids are one of the ﬁrst plaque
components to disappear from the vessel wall and are sub-
sequently replaced by collagen and smooth muscle cells as
markers of plaque stabilization (40–42). Therefore, imaging
changes in the oxidized lipid content of plaques may provide
a unique and informative index of rapid changes in plaque
composition before anatomic plaque regression, which may
reﬂect clinical beneﬁt.
Future studies linking release of such OxPL with
periprocedural clinical events are needed to conﬁrm this
hypothesis. If this is conﬁrmed, therapeutic agents to target
oxidized lipids, such as human and “natural” oxidation-
speciﬁc antibodies (9,43), could be infused during acute cor-
onary syndrome/ST-segment elevation myocardial infarction
or just before percutaneous interventions to bind the released
Figure 6
Normal-Phase HPLC-MS/MS Analysis of Cholesteryl Esters Extracted From a Distal Protection Filter After
Human SVG Procedure
Data were collected in MRM mode. (A) Solid chromatograms show CE(18:2) and its oxidation products; dashed chromatograms represent CE(20:4) and its oxidation products.
Families of structurally related oxidation products are labeled with the characteristic oxygen moiety, for example, the group of peaks labeled “hydroxy” are isomers of CE(HODE)
(solid line) and CE(HETE) (dashed line). (B) Estimated CE oxidation as a percent of the total CE pool in SVG ﬁlter device samples is determined by peak area ratios of the 3 major
cholesteryl esters (CEs) (18:2, 20:4, 22:6) and their various oxidation products by MRM analysis. (C) Relative quantitation was assessed by normal-phase HPLC-MS/MS as
described in the Online Appendix. Solid bars indicate the relative abundance of the 3 major CE species; the summed oxidation products of each CE species are indicated
by open bars.
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1969oxidized lipids and prevent their interaction with platelets
and endothelial cells, thus potentially abrogating vasocons-
triction, no-reﬂow phenomenon, and thrombosis (16,29,30).
Study limitations. Complete oxidized lipidomics of non–
PC-based OxPL was not performed, and it is possible that
non–PC-based OxPL also have pathophysiological roles.However, PC-based phospholipids are in the greatest
abundance and the most well characterized. Small changes
in the oxidized lipid proportions may have occurred as
the result of ex vivo oxidation despite the use of ethyl-
enediaminetetraacetic acid/butylated hydroxytoluene and
careful handling, as suggested by Liu et al. (44).
Figure 7 Immunostaining of Material Derived From SVG Filters for OxPL Epitopes and Malondialdehyde Epitopes
Immunostaining of material derived from SVG ﬁlters for OxPL epitopes stained with antibody E06 and malondialdehyde epitopes stained with guinea pig polyclonal antibody
MDA3.
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1970Conclusions
This study documents that OxPL and OxCE are released
downstream from symptomatic lesions during percutaneous
interventions from multiple arterial beds. These ﬁndings
support the testable hypothesis that pre-treatment of pati-
ents undergoing such procedures with oxidation-speciﬁc
antibodies to inactivate bioactive oxidized lipids released into
the microcirculation may provide clinical beneﬁt.
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APPENDIX
For an expanded Methods section, please see the online version of this
article.
